• KOL
    • Psoriatic Arthritis
    • Arthur F Kavanaugh
    • Arthur F Kavanaugh: Influence Statistics

      Arthur F Kavanaugh

      Arthur F Kavanaugh

      Show email address

      Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, United States | A. Kavanaugh, MD, Division of Rheumatology, Allergy and ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Arthur F Kavanaugh:Expert Impact

      Concepts for whichArthur F Kavanaughhas direct influence:Psoriatic arthritis,Rheumatoid arthritis,Psoriatic arthritis psa,Week patients,Patients psa,Patients psoriatic arthritis,Celgene corporation,Bristolmyers squibb.

      Arthur F Kavanaugh:KOL impact

      Concepts related to the work of other authors for whichfor which Arthur F Kavanaugh has influence:Rheumatoid arthritis,Autoimmune diseases,Systemic lupus erythematosus,Monoclonal antibodies,Necrosis factor,Ankylosing spondylitis,Radiographic progression.

      KOL Resume for Arthur F Kavanaugh

      Year
      2022

      Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, United States

      A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California, USA.

      Rheumatology, University of California, San Diego, CA

      University of California San Diego, La Jolla

      2021

      University of California San Diego

      2020

      University of California San Diego School of Medicine, La Jolla, CA, USA

      2019

      San Diego School of Medicine, University of California, La Jolla, CA

      Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary.

      2018

      University of California, San Diego, La Jolla

      UCSD, San Diego, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Arthur F Kavanaugh is among the top experts in the world.
      Concept World rank
      wk 104 #1
      week assessments #1
      amdf modified cpdai #1
      igg ssi monoclonal #1
      synovial tissue arthroscopy #1
      pharmaceutical humans receptors #1
      pasi dlqi responses #1
      rheumatology studies #1
      pfizer celgene #1
      adacta tcztreated patients #1
      nadab #1
      pasi cdapsa #1
      24 improvements #1
      anxiety depression fatigue #1
      biologic modulators #1
      imaging radiologist #1
      psa treatment #1
      eair patients #1
      9 months hiit #1
      secukinumab 75 patients #1
      bedside immunopathogenesis #1
      psolarmethodspsolar #1
      older adults pmr #1
      biologic discontinuation #1
      mdana #1
      patients dapsa ≤ #1
      nadab association #1
      total igm igg #1
      rapid3 dapsa #1
      evaluating disease activity #1
      greater proportions #1
      randomized pbo #1
      pfizer celgene corporation #1
      weeks physical function #1
      psa report #1
      predictors tnfi initiation #1
      training joints #1
      variance examiners #1
      mtx adacta #1
      patients psa guidelines #1
      spondyloarthropathies psoriatic arthritis #1
      pasi dapsa #1
      interleukin17a patients #1
      clinical measure month #1
      ambition tcztreated patients #1
      sdai pasi #1
      aspects rheumatoid arthritis #1
      24 weeks data #1
      acr50 rates #1
      dapsa ticopa #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Arthur F Kavanaugh

      KOL-Index: 25920

      OBJECTIVE: Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We investigated the ability of adalimumab, a human anti-TNF monoclonal antibody, to inhibit the progression of structural joint damage, reduce the signs and symptoms, and improve physical function in patients with active RA receiving concomitant treatment with methotrexate (MTX).

      METHODS: In this multicenter, ...

      Known for Adalimumab Patients | Active Rheumatoid | Physical Function | Arthritis Receiving | Factor Monoclonal
      KOL-Index: 22236

      OBJECTIVE: To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment.

      METHODS: This was a 2-year, multicenter, double-blind, active comparator-controlled study of 799 RA patients with active disease of < 3 years' duration who had never been treated with MTX. Treatments included adalimumab 40 mg subcutaneously every ...

      Known for Combination Therapy | Adalimumab Mtx | Clinical Trial | Methotrexate Treatment | Premier Study
      KOL-Index: 21052

      BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.

      METHODS: This trial was done at 161 sites worldwide. ...

      Known for Methotrexate Patients | Low Disease | Rheumatoid Arthritis | Primary Endpoint | Activity Adalimumab
      KOL-Index: 20284

      BACKGROUND: Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endpoint of American College of Rheumatology (ACR) 20 response.

      METHODS: This parallel-group, double-blind, active-controlled, phase-3b, multicentre (168 sites in 26 countries) ...

      Known for Secukinumab Adalimumab | Psoriatic Arthritis | Week Patients | Primary Endpoint | Safety Treatment
      KOL-Index: 19153

      OBJECTIVE: To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA).

      METHODS: Adult patients with PsA who had at least 3 swollen and 3 tender joints and active psoriasis were randomly assigned to receive subcutaneous injections of placebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146) every 4 weeks through week 20. Efficacy assessments through week 24 included the American College of Rheumatology 20% improvement criteria ...

      Known for Golimumab Patients | Psoriatic Arthritis | Subcutaneous Injection | Necrosis Factor | Efficacy Safety
      KOL-Index: 18907

      BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.

      METHODS: We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 ...

      Known for Adalimumab Monotherapy | Rheumatoid Arthritis | Patients Tocilizumab | Baseline Das28 | Phase 4
      KOL-Index: 18792

      OBJECTIVE: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents.

      METHODS: In this phase 3, multicentre, placebo-controlled trial, 312 adults with active PsA were randomised (stratified by site, weight (≤100 kg/>100 kg), methotrexate use) to ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks or placebo at week ...

      Known for Active Psoriatic Arthritis | Necrosis Factor | Week Patients | Monoclonal Antibodies | Ustekinumab Efficacy
      KOL-Index: 18586

      INTRODUCTION: The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA).

      METHODS: Patients with active RA (N = 982) were randomized 2:2:1 to subcutaneous CZP (400 mg at weeks 0, 2 and 4; followed by CZP 200 mg or 400 mg) plus methotrexate (MTX) every other week, or placebo (PBO) plus MTX. PRO assessments included HRQoL, ...

      Known for Arthritis Patients | Certolizumab Pegol | Controlled Trial | Improvements Pros | Life Fatigue
      KOL-Index: 18321

      BACKGROUND: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis.

      METHODS: In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Australia, Canada, Europe, and the USA, adults (aged ≥18 years old) with active psoriatic arthritis were randomly ...

      Known for Psoriatic Arthritis | Patients Week | Secukinumab 300 | 3 Trial | 75 Placebo
      KOL-Index: 17402

      OBJECTIVE: To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA).

      METHODS: One hundred four patients with PsA in whom prior therapy with at least 1 disease-modifying antirheumatic drug (DMARD) had failed were recruited into this investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial. During the initial blinded portion of the study, patients received ...

      Known for Infliximab Therapy | Psoriatic Arthritis | Week Patients | Dactylitis Enthesitis | Controlled Trial
      KOL-Index: 17386

      BACKGROUND: Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor.

      OBJECTIVE: To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (MTX), in patients with active rheumatoid arthritis (RA).

      METHODS: An international, multicentre, phase 3, randomised, double-blind, placebo-controlled study in active adult-onset RA. Patients (n = 619) were randomised 2:2:1 to subcutaneous certolizumab pegol (liquid formulation) 400 mg at weeks 0, 2 and 4 ...

      Known for Certolizumab Pegol | Monoclonal Antibodies | Humanized Arthritis | Mtx Placebo | Physical Function
      KOL-Index: 16573

      BACKGROUND: Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis.

      METHODS: In this phase 3, multicentre, double-blind, ...

      Known for Placebo Week | 1 Year | Active Psoriatic | Humanized Arthritis | Phase 3
      KOL-Index: 15359

      BACKGROUND: Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A and IL17F, in patients with active psoriatic arthritis.

      METHODS: BE ACTIVE was a randomised, double-blind, placebo-controlled, dose-ranging phase 2b study done at 41 sites in the Czech Republic, Germany, Hungary, Poland, Russia, and the USA. Eligible ...

      Known for Psoriatic Arthritis | Patients Bimekizumab | Phase 2b | Weeks 12 | Assigned Placebo
      KOL-Index: 14921

      OBJECTIVES: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.

      METHODS: In the 24-week, placebo-controlled phase of PALACE 1, patients (N=504) were randomised (1:1:1) to placebo, apremilast 20 mg twice a day ...

      Known for Oral Phosphodiesterase | 4 Inhibitor | Psoriatic Arthritis | Placebo Patients | 30 Bid Week
      KOL-Index: 14800

      OBJECTIVE: To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA).

      METHODS: In this phase III, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive IV placebo (n = 239) or golimumab at 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 14. ...

      Known for Intravenous Golimumab | Week Patients | Psoriatic Arthritis Psa | Acr20 Response | Agents Arthritis

      Key People For Psoriatic Arthritis

      Top KOLs in the world
      #1
      D Gladman Gladman
      psoriatic arthritis systemic lupus erythematosus patients psa
      #2
      Philip J Mease
      psoriatic arthritis eli lilly novartis pfizer
      #3
      Philip S Helliwell
      psoriatic arthritis tight control axial involvement
      #4
      Oliver M FitzGerald
      psoriatic arthritis synovial tissue patients psa
      #5
      Christopher T Ritchlin
      psoriatic arthritis radiographic progression janssen development
      #6
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression

      Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, United States | A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California, USA. | Rheumatology,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.